Bridging the digital divide in the pharmaceutical industry: A future research agenda

Digital transformation is reshaping the pharmaceutical industry, but adoption remains fragmented due to regulatory constraints, organizational inertia, and unequal digital capabilities. This study investigates how the digital divide influences the implementation of new technologies across the pharmaceutical value chain. We combined a systematic literature review of 70 peer-reviewed studies with topic modeling (Latent Dirichlet Allocation) to provide an integrated overview of challenges, opportunities, and future research directions. Our analysis identified 16 thematic clusters consolidated into five strategic domains: Advancing Drug Discovery, Reinventing Organizational Strategies, Optimizing Manufacturing, Strengthening Supply Chains, and Developing Patient-Centric Models. The results show that digital transformation is not only a technical matter but also a systemic process shaped by regulation, governance, and socio-economic conditions. While artificial intelligence, blockchain, digital twins, and other technologies hold potential to accelerate innovation and improve patient outcomes, their benefits are distributed unevenly. Large multinational firms, advanced laboratories, and well-resourced health systems are better positioned to adopt these tools, while small and medium enterprises, emerging economies, and marginalized patient groups often face barriers in infrastructure, expertise, and compliance. From these findings, we developed a structured research agenda to bridge the pharmaceutical digital divide. Priorities include clarifying regulatory and institutional frameworks for digital technologies, identifying the organizational capabilities and governance models required for systemic adoption, and addressing equity implications to ensure inclusive access across geographies, firms, and patient populations. This study contributes methodologically by integrating systematic review and topic modeling, conceptually by framing digital transformation through a value-chain and digital divide perspective, and practically by offering a roadmap for managers, policymakers, and scholars.

Authors

Institutions

Publication Details

Journal
Social Science & Medicine
Published
2025-11-28
DOI
https://doi.org/10.1016/j.socscimed.2025.118832
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bridging the digital divide in the pharmaceutical industry: A future research agenda

Salvatore Lombardo, Mario Miozza, Luca Magni, Marco Galvagno
Social Science & Medicine
Pharmaceutical Economics and Policy
article

Bridging the digital divide in the pharmaceutical industry: A future research agenda

Salvatore Lombardo, Mario Miozza, Luca Magni, Marco Galvagno
article en

Abstract

Digital transformation is reshaping the pharmaceutical industry, but adoption remains fragmented due to regulatory constraints, organizational inertia, and unequal digital capabilities. This study investigates how the digital divide influences the implementation of new technologies across the pharmaceutical value chain. We combined a systematic literature review of 70 peer-reviewed studies with topic modeling (Latent Dirichlet Allocation) to provide an integrated overview of challenges, opportunities, and future research directions. Our analysis identified 16 thematic clusters consolidated into five strategic domains: Advancing Drug Discovery, Reinventing Organizational Strategies, Optimizing Manufacturing, Strengthening Supply Chains, and Developing Patient-Centric Models. The results show that digital transformation is not only a technical matter but also a systemic process shaped by regulation, governance, and socio-economic conditions. While artificial intelligence, blockchain, digital twins, and other technologies hold potential to accelerate innovation and improve patient outcomes, their benefits are distributed unevenly. Large multinational firms, advanced laboratories, and well-resourced health systems are better positioned to adopt these tools, while small and medium enterprises, emerging economies, and marginalized patient groups often face barriers in infrastructure, expertise, and compliance. From these findings, we developed a structured research agenda to bridge the pharmaceutical digital divide. Priorities include clarifying regulatory and institutional frameworks for digital technologies, identifying the organizational capabilities and governance models required for systemic adoption, and addressing equity implications to ensure inclusive access across geographies, firms, and patient populations. This study contributes methodologically by integrating systematic review and topic modeling, conceptually by framing digital transformation through a value-chain and digital divide perspective, and practically by offering a roadmap for managers, policymakers, and scholars.

Social Science & MedicineVol. 389
University of Catania (IT), Libera Università Internazionale degli Studi Sociali Guido Carli (IT), University of Bologna (IT)
Openalex Percentile: Top 56%
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.